TABLE 2

Geometric means and univariate and adjusted geometric mean ratios with 95% CI comparing the Cmaxs and the AUC0–6 of anti-TB drugs in patients with DM versus patients without DMa

Drug, phase, and parameterGeometric mean value for patients with:GMR (95% CI)P value for GMRAdjusted GMR (95% CI)P value for adjusted GMR
No diabetesDiabetes
Rifampin
    Intensive phase
        Cmax (μg/ml)4.323.630.84 (0.62, 1.14)0.260.75 (0.48, 1.19)0.22
        AUC0–6 (μg · h/ml)15.3412.190.79 (0.60, 1.05)0.110.79 (0.55, 1.15)0.22
    Continuation phase
        Cmax (μg/ml)2.983.811.28 (0.90, 1.82)0.171.00 (0.67, 1.49)0.99
        AUC0–6 (μg · h/ml)11.1314.461.30 (0.92, 1.84)0.141.08 (0.73, 1.61)0.69
Isoniazid
    Intensive phase
        Cmax (μg/ml)7.915.970.75 (0.58, 0.98)0.030.77 (0.56, 1.03)0.08
        AUC0–6 (μg · h/ml)26.8420.00.75 (0.57, 0.97)0.030.74 (0.54, 1.01)0.06
    Continuation phase
        Cmax (μg/ml)7.637.420.97 (0.72, 1.32)0.860.82 (0.53, 1.27)0.38
        AUC0–6 (μg · h/ml)26.7923.790.89 (0.65, 1.21)0.450.75 (0.50, 1.14)0.18
Pyrazinamide, intensive phase
    Cmax (μg/ml)32.7521.590.66 (0.51, 0.85)0.0020.74 (0.56, 0.97)0.03
    AUC0–6 μg · h/ml)128.4380.890.63 (0.49, 0.80)<0.0010.65 (0.49, 0.86)0.003
  • a The models are adjusted for age, sex, and weight. Visit 1 was during the intensive phase of TB treatment, while visit 2 took place during the continuation phase of TB treatment. GMR, geometric mean ratio.